News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
778,788 Results
Type
Article (54963)
Company Profile (642)
Press Release (723183)
Multimedia
Podcasts (107)
Webinars (13)
Section
Business (224200)
Career Advice (3249)
Deals (38805)
Drug Delivery (125)
Drug Development (87577)
Employer Resources (193)
FDA (17541)
Job Trends (16739)
News (379955)
Policy (36845)
Tag
Academia (2880)
Academic (1)
Accelerated approval (6)
Adcomms (27)
Allergies (96)
Alliances (55046)
ALS (104)
Alzheimer's disease (1490)
Antibody-drug conjugate (ADC) (162)
Approvals (17500)
Artificial intelligence (296)
Autoimmune disease (29)
Automation (16)
Bankruptcy (400)
Best Places to Work (12494)
BIOSECURE Act (22)
Biosimilars (117)
Biotechnology (438)
Bladder cancer (85)
Brain cancer (30)
Breast cancer (308)
Cancer (2466)
Cardiovascular disease (205)
Career advice (2737)
Career pathing (34)
CAR-T (174)
Cell therapy (484)
Cervical cancer (21)
Clinical research (71031)
Collaboration (932)
Company closure (2)
Compensation (576)
Complete response letters (29)
COVID-19 (2851)
CRISPR (49)
C-suite (275)
Cystic fibrosis (108)
Data (2356)
Decentralized trials (2)
Denatured (34)
Depression (56)
Diabetes (301)
Diagnostics (6868)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (47)
Drug discovery (130)
Drug pricing (127)
Drug shortages (32)
Duchenne muscular dystrophy (103)
Earnings (93489)
Editorial (46)
Employer branding (24)
Employer resources (164)
Events (125168)
Executive appointments (783)
FDA (18957)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (822)
Gene editing (124)
Generative AI (28)
Gene therapy (358)
GLP-1 (852)
Government (4899)
Grass and pollen (6)
Guidances (150)
Healthcare (20452)
Huntington's disease (25)
IgA nephropathy (30)
Immunology and inflammation (150)
Indications (30)
Infectious disease (3013)
Inflammatory bowel disease (158)
Inflation Reduction Act (10)
Influenza (57)
Intellectual property (102)
Interviews (614)
IPO (17700)
IRA (50)
Job creations (4722)
Job search strategy (2259)
Kidney cancer (11)
Labor market (46)
Layoffs (558)
Leadership (24)
Legal (9287)
Liver cancer (81)
Lung cancer (347)
Lymphoma (161)
Machine learning (9)
Management (64)
Manufacturing (361)
MASH (81)
Medical device (14492)
Medtech (14497)
Mergers & acquisitions (21672)
Metabolic disorders (797)
Multiple sclerosis (88)
NASH (23)
Neurodegenerative disease (114)
Neuropsychiatric disorders (34)
Neuroscience (2100)
NextGen: Class of 2025 (7391)
Non-profit (4877)
Now hiring (41)
Obesity (429)
Opinion (273)
Ovarian cancer (82)
Pain (104)
Pancreatic cancer (91)
Parkinson's disease (161)
Partnered (24)
Patents (255)
Patient recruitment (119)
Peanut (51)
People (63099)
Pharmaceutical (132)
Pharmacy benefit managers (22)
Phase I (22109)
Phase II (31182)
Phase III (23324)
Pipeline (1396)
Policy (178)
Postmarket research (2886)
Preclinical (9458)
Press Release (72)
Prostate cancer (114)
Psychedelics (38)
Radiopharmaceuticals (268)
Rare diseases (431)
Real estate (6833)
Recruiting (74)
Regulatory (24994)
Reports (53)
Research institute (2574)
Resumes & cover letters (516)
Rett syndrome (5)
RNA editing (5)
RSV (50)
Schizophrenia (81)
Series A (144)
Series B (93)
Service/supplier (27)
Sickle cell disease (59)
Special edition (20)
Spinal muscular atrophy (160)
Sponsored (32)
Startups (4166)
State (2)
Stomach cancer (16)
Supply chain (75)
Tariffs (54)
The Weekly (71)
Vaccines (815)
Venture capitalists (45)
Weight loss (298)
Women's health (38)
Worklife (20)
Date
Last 7 days (980)
Last 30 days (3126)
Last 365 days (34599)
2025 (12428)
2024 (37677)
2023 (42454)
2022 (53779)
2021 (58541)
2020 (57265)
2019 (50455)
2018 (38346)
2017 (35828)
2016 (36075)
2015 (42068)
2014 (36185)
2013 (31260)
2012 (33273)
2011 (33698)
2010 (31973)
Location
Africa (975)
Alabama (61)
Alaska (7)
Arizona (256)
Arkansas (14)
Asia (45193)
Australia (7584)
California (6665)
Canada (2103)
China (574)
Colorado (287)
Connecticut (303)
Delaware (166)
Europe (100972)
Florida (974)
Georgia (226)
Hawaii (1)
Idaho (62)
Illinois (599)
India (30)
Indiana (341)
Iowa (12)
Japan (177)
Kansas (113)
Kentucky (27)
Louisiana (14)
Maine (70)
Maryland (983)
Massachusetts (5098)
Michigan (248)
Minnesota (428)
Mississippi (2)
Missouri (90)
Montana (30)
Nebraska (26)
Nevada (69)
New Hampshire (69)
New Jersey (1874)
New Mexico (31)
New York (1872)
North Carolina (1134)
North Dakota (9)
Northern California (2876)
Ohio (224)
Oklahoma (14)
Oregon (46)
Pennsylvania (1463)
Puerto Rico (14)
Rhode Island (36)
South America (1412)
South Carolina (26)
South Dakota (1)
Southern California (2473)
Tennessee (106)
Texas (993)
United States (25353)
Utah (199)
Virginia (171)
Washington D.C. (72)
Washington State (610)
West Virginia (3)
Wisconsin (69)
778,788 Results for "warner lambert company merged with pfizer see pfizer inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Pfizer Sees Path to Braftovi’s Full Approval With Phase III CRC Data
Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the way for its full approval for the treatment of certain colorectal cancers, according to the company.
February 3, 2025
·
2 min read
·
Tristan Manalac
Earnings
Pfizer Announces Another $1.7B in Cost Savings, Including R&D Revamp
Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist Seagen. The new cuts were revealed in the company’s Q1 earnings report.
April 29, 2025
·
2 min read
·
Annalee Armstrong
Bladder cancer
Pfizer’s Subcutaneous PD-1 Cuts Risks in Bladder Cancer but Misses Survival Endpoint
Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due to any cause or persistence of cancer cells by 32% in patients with high-risk non-muscle invasive bladder cancer.
April 28, 2025
·
1 min read
·
Tristan Manalac
Cardiovascular disease
Pfizer Mounts Defense of Cardiac Blockbuster as Alnylam, BridgeBio Enter Market
Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.
April 22, 2025
·
5 min read
·
Nick Paul Taylor
Podcast
Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed
Donald Trump takes biopharma on a tariff-themed rollercoaster ride; J&J kicks off the Q1 earnings season; experts express concern about the FDA’s future; Pfizer’s obesity setback could be Viking’s gain; and BioSpace reveals the highest paid pharma CEOs.
April 16, 2025
·
1 min read
·
Heather McKenzie
Weight Loss
Viking Rises as Pfizer’s Oral Obesity Med Falters
Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron. But the biotech has a long way to go to recover after six straight months of decline.
April 14, 2025
·
3 min read
·
Annalee Armstrong
Weight loss
Pfizer Drops Lead Obesity Asset After Liver Safety Concerns, Overall Review
Pfizer’s discontinuation of danuglipron brings the company down to a single molecule in its obesity pipeline.
April 14, 2025
·
2 min read
·
Tristan Manalac
Pipeline
Pfizer’s Pipeline Pruning Ends Early-Stage STING Trial
Pfizer was studying PF-07820435, an orally available agonist of the STING protein, for solid tumors.
March 14, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
How SpringWorks Took Pfizer’s Rare Disease Ghost Drug and Got It to Patients
SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for neurofibromatosis alive. This method could work for “every rare disease under the sun,” advocates say.
February 26, 2025
·
5 min read
·
Annalee Armstrong
Gene therapy
Pfizer Axes Beqvez Worldwide, Pivoting Away From Gene Therapy for Hemophilia
The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.
February 21, 2025
·
2 min read
·
Tristan Manalac
1 of 77,879
Next
